IDXX vs. ALC, CNC, HUM, IQV, HLN, TAK, GEHC, COR, MRNA, and BIIB
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Alcon (ALC), Centene (CNC), Humana (HUM), IQVIA (IQV), Haleon (HLN), Takeda Pharmaceutical (TAK), GE HealthCare Technologies (GEHC), Cencora (COR), Moderna (MRNA), and Biogen (BIIB). These companies are all part of the "medical" sector.
IDEXX Laboratories (NASDAQ:IDXX) and Alcon (NYSE:ALC) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, community ranking, earnings, dividends and profitability.
IDEXX Laboratories has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, Alcon has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.
IDEXX Laboratories received 351 more outperform votes than Alcon when rated by MarketBeat users. Likewise, 72.58% of users gave IDEXX Laboratories an outperform vote while only 60.92% of users gave Alcon an outperform vote.
IDEXX Laboratories has a net margin of 23.26% compared to Alcon's net margin of 10.30%. IDEXX Laboratories' return on equity of 63.66% beat Alcon's return on equity.
In the previous week, Alcon had 7 more articles in the media than IDEXX Laboratories. MarketBeat recorded 15 mentions for Alcon and 8 mentions for IDEXX Laboratories. IDEXX Laboratories' average media sentiment score of 1.00 beat Alcon's score of 0.55 indicating that IDEXX Laboratories is being referred to more favorably in the media.
IDEXX Laboratories currently has a consensus price target of $580.88, suggesting a potential upside of 15.48%. Alcon has a consensus price target of $91.22, suggesting a potential upside of 12.75%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Alcon.
87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 53.9% of Alcon shares are owned by institutional investors. 2.1% of IDEXX Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Alcon has higher revenue and earnings than IDEXX Laboratories. Alcon is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
IDEXX Laboratories beats Alcon on 14 of the 18 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
